Workup of Streptococcus agalactiae (Group B Streptococcus) UTIs
For GBS bacteriuria in pregnancy, no additional workup beyond the positive urine culture is needed—the patient should receive intrapartum antibiotic prophylaxis regardless of colony count, and routine third-trimester screening should be omitted. For non-pregnant adults, the workup should focus on identifying underlying risk factors and determining whether treatment is indicated based on symptoms and clinical context.
Pregnant Patients
Initial Management
- Any level of GBS bacteriuria (regardless of CFU/mL) in pregnancy automatically qualifies the patient for intrapartum antibiotic prophylaxis 1, 2.
- Laboratories should report GBS in urine when present at concentrations ≥10⁴ CFU/mL in pure culture or mixed with a second microorganism 1.
- Clinicians must inform laboratories when submitted urine specimens are from pregnant women to ensure proper testing 1.
Treatment Approach
- Treat symptomatic bacteriuria with colony counts ≥100,000 CFU/mL with appropriate oral antibiotics at the time of diagnosis 2.
- For asymptomatic bacteriuria with colony counts <100,000 CFU/mL, do not treat with antibiotics during pregnancy—reserve treatment for intrapartum prophylaxis only 2.
- Women with documented GBS bacteriuria should not undergo repeat genital tract or urinary cultures in the third trimester, as they are presumed to remain colonized 2.
Antibiotic Selection for Intrapartum Prophylaxis
- Penicillin G remains the agent of choice: 5 million units IV initial dose, then 2.5-3.0 million units every 4 hours until delivery 1.
- Ampicillin is an acceptable alternative: 2 g IV initial dose, then 1 g IV every 4 hours until delivery 1.
- For penicillin-allergic patients without high-risk features (no history of anaphylaxis, angioedema, respiratory distress, or urticaria): cefazolin 2 g IV initial dose, then 1 g IV every 8 hours 1.
- For penicillin-allergic patients at high risk for anaphylaxis: perform antimicrobial susceptibility testing for clindamycin and erythromycin on the GBS isolate 1.
Key Pitfall to Avoid
The CDC guidelines emphasize that pregnant women with GBS bacteriuria do not need vaginal-rectal screening at 35-37 weeks, as they are already considered colonized 2. This prevents unnecessary duplicate testing and ensures appropriate intrapartum prophylaxis.
Non-Pregnant Adults
Risk Factor Assessment
- Age is a critical prognostic indicator: Women over 40 years, particularly those over 60 years, represent the highest-risk group for GBS UTI 3, 4.
- Identify underlying conditions: Diabetes mellitus significantly increases risk for invasive GBS urogenital infections 5; chronic diseases and urinary tract abnormalities are present in 26.4% of non-pregnant women with GBS bacteriuria 4.
- Gender considerations: Men with GBS UTI universally have underlying chronic diseases 4.
Clinical Categorization
- Uncomplicated cystitis accounts for 66.1% of GBS UTI cases in non-pregnant adults 4.
- Complicated infection occurs in 19.1% of cases 4.
- Asymptomatic bacteriuria represents 11.8% of cases 4.
- Pyuria is present in 72.9% of GBS UTI cases, but semi-quantitative bacteruria counts have no significant predictive value for differentiating acute UTI from asymptomatic bacteriuria 3.
Laboratory Workup
- Urine culture with colony count determination is essential for diagnosis 6.
- Antimicrobial susceptibility testing should be performed, as high resistance rates exist: tetracycline (81.5-88.46%), clindamycin (26-77.34%), erythromycin (36.3-44.5%), and azithromycin (44.5%) 7, 8, 9.
- Universal susceptibility to penicillin, ampicillin, cefuroxime, cefaclor, ceftriaxone, and vancomycin has been documented 7, 8.
- Multidrug resistance occurs in 33.6% of GBS UTI isolates 9.
Additional Workup Considerations
- Proteinuria and hematuria on urinalysis are significantly associated with acute infection rather than asymptomatic bacteriuria 3.
- For women under 40 years with recurrent UTI and no risk factors, extensive routine workup (cystoscopy, full abdominal ultrasound) is not recommended 6.
- Capsular types III, Ia, V, Ib, and IX predominate in GBS UTI, with type III associated with tetracycline resistance and type Ib with levofloxacin resistance 7.
Treatment Guidance
- First-line agents: Penicillin or ampicillin remain the drugs of choice given universal susceptibility 7, 8.
- Alternative agents: Cephalosporins and vancomycin are fully effective 7, 8.
- Avoid empiric use of macrolides, clindamycin, or tetracyclines without susceptibility testing due to high resistance rates 7, 8, 9.
- For symptomatic patients whose symptoms do not resolve by end of treatment, perform repeat urine culture and susceptibility testing, then retreat with a 7-day regimen using a different agent 6.
Clinical Context
GBS represents a rare but emerging pathogen in UTIs, particularly in women of childbearing age (25-34 years show increased odds ratio of 1.91) 8. The association with diabetes mellitus warrants particular attention, as DM increases risk for invasive GBS urogenital infections through immunologic and metabolic mechanisms 5.